

TB ShORRT UK: an observational study of new, shorter treatment regimens for drug-resistant tuberculosis in the UK

Submission date 20/12/2022	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/08/2023	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 31/07/2023	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Until 2022 most people treated for drug-resistant TB in the world received treatment courses of 12-18 months with at least 5 toxic drugs including daily intra-muscular injections with a drug that carried a high risk of causing hearing loss.

Fortunately medical researchers have recently discovered new highly effective drug regimens which are shorter (6 months) and use therapies with fewer side effects (no deafness) not requiring injections.

TB ShORRT UK is designed to determine whether these new treatment regimens for drug-resistant TB will perform as well in the UK context, by recording and following closely the experiences of TB patients treated with them in the UK. The study protocol is derived from a World Health Organisation template and there are similar studies underway in more than a dozen other countries.

Who can participate?

Any patient of any age receiving TB treatment that is not the standard 'first-line' regimen will be eligible to take part - most participants will be people with drug-resistant TB but people unable to tolerate 'first-line' treatments will also be invited to join.

What does the study involve?

No additional tests or interventions will be required for the study. Data will be collected from the usual clinical visit schedule.

What are the possible benefits and risks of participating?

There are no risks to participation - treatment will be unchanged and there are no additional clinic visits or tests to those that would ordinarily be the 'standard of care' expected - the data (blood test results, weight, symptoms) will be recorded and analysed together with those of other patients.

Where is the study run from?

University College London Hospitals NHS Foundation Trust

When is the study starting and how long is it expected to run for?
February 2022 to February 2028

Who is funding the study?
The study team are applying for funding from NIHR (Research for Patient Benefit scheme)

Who is the main contact?
Prof Dave Moore, davidajmoore1@nhs.net

Contact information

Type(s)
Principal Investigator

Contact name
Prof Dave Moore

ORCID ID
<http://orcid.org/0000-0002-3748-0154>

Contact details
Hospital for Tropical Diseases
2nd Floor, Maple House
University College London Hospitals NHS Trust
London
United Kingdom
W1T 7NF
+44 20 3456 7890
davidajmoore1@nhs.net

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
317172

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
IRAS 317172

Study information

Scientific Title
TB ShORRT UK: an implementation evaluation of shorter, all-oral regimens for drug-resistant tuberculosis in the United Kingdom

Acronym

TB ShORRT UK

Study objectives

Novel, shorter regimens for treatment of MDRTB have been recommended by the WHO. In clinical trials these have been shown to be better tolerated and more efficacious than existing drug regimens. To accelerate adoption in countries, local demonstration of comparative performance, tolerability and acceptability to patients and healthcare staff is critical. This implementation research project, closely mirroring the parent template protocol developed by WHO/TDR, will gather the evidence required to determine if such regimens are well suited to the UK context and inform future policy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Observational cohort study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Tuberculosis resistant to first-line drug therapies or tuberculosis in patients intolerant of first-line drug therapies

Interventions

UK TB patients with drug-resistant TB or intolerant of first-line TB medications will receive regimens composed of second-line therapies as part of their standard of care. All such patients will be invited to participate in an observational cohort study to advance our understanding of the safety, tolerability and efficacy of new, shorter, all-oral treatment regimens which are being introduced worldwide, and presently in the UK. No additional tests or interventions will be required for the study. Standardised collection of data from usual clinical visit schedule will facilitate aggregate analyses.

Intervention Type

Mixed

Primary outcome measure

1. Effectiveness, defined as the proportion of patients with a favourable outcome of "cured" or "treatment completed without clinical or bacteriologic evidence of failure" up to 12 months after the end of treatment
2. Safety, assessed as the proportion of patients experiencing a serious adverse event during treatment and up to 6 months after the end of treatment

Secondary outcome measures

1. Health-related quality of life, assessed using the EQ-5D-5L and FACIT-TB questionnaires at baseline, 4 months, end of treatment and 12 months after treatment completion
2. Stigma, assessed using the Modified Cataldo Lung Cancer Scale at baseline, 4 months, end of treatment and 12 months after treatment completion
3. Acceptability to healthcare workers, assessed using semi-structured interviews and framework analysis with two rounds of interviews 12-18 months apart
4. Cost-effectiveness of shorter all-oral regimens compared to longer course regimens, utilising a Markov model to assess the incremental cost incurred per QALY gained

Overall study start date

01/02/2022

Completion date

28/02/2028

Eligibility

Key inclusion criteria

UK TB patients receiving a treatment regimen other than first-line treatment

Participant type(s)

Patient

Age group

All

Sex

Both

Target number of participants

800

Key exclusion criteria

1. Patients unable or unwilling to provide informed consent

Date of first enrolment

01/11/2023

Date of final enrolment

28/02/2027

Locations

Countries of recruitment

England

Northern Ireland

Scotland

United Kingdom

Wales

Study participating centre

University College London Hospitals NHS Foundation Trust

250 Euston Road

London

United Kingdom

NW1 2PG

Sponsor information

Organisation

University College London Hospitals NHS Foundation Trust

Sponsor details

235 Euston Rd

London

England

United Kingdom

NW1 2BU

+44 20 3456 7890

uclh.randd@nhs.net

Sponsor type

Hospital/treatment centre

Website

<https://www.uclh.nhs.uk/Pages/home.aspx>

ROR

<https://ror.org/042fqyp44>

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded at present - funding application in process

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Planned dissemination of results to all participants and PPI group in separate workshops.

Intention to publish date

31/03/2026

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at later date

IPD sharing plan summary

Data sharing statement to be made available at a later date